Harding Loevner LP Neurocrine Biosciences Inc Transaction History

Harding Loevner LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $3,957 - $4,635	-43 Reduced 5.31%	767 $81,000
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $2,390 - $3,128	33 Added 4.25%	810 $61,000
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $17,124 - $22,837	215 Added 38.26%	777 $66,000
Q3 2020 Nov 16, 2020	BUY	$96.16 - $135.15 $29,424 - $41,355	306 Added 119.53%	562 $54,000
Q1 2020 May 15, 2020	BUY	$75.11 - $113.76 $19,228 - $29,122	256 New	256 $22,000

654

96.5M

282K

281K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.4B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Harding Loevner LP, based on Form 13F filings with the SEC.

Stay updated on Harding Loevner LP with notifications on news.